Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) news covers a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals. The company’s updates frequently highlight progress across its crofelemer programs, regulatory interactions, and partnerships.
Investors following JAGX news can expect coverage of developments related to Mytesi, Napo Pharmaceuticals’ FDA-approved crofelemer product for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, as well as Jaguar’s broader intestinal failure program targeting rare disorders such as short bowel syndrome with intestinal failure (SBS-IF) and microvillus inclusion disease (MVID). News items often describe clinical trial milestones, proof-of-concept data on reductions in parenteral support, and discussions with regulators about potential expedited approval pathways for ultrarare pediatric indications.
On the animal health side, Jaguar news includes information about Canalevia-CA1, the company’s conditionally approved crofelemer-based prescription drug for chemotherapy-induced diarrhea in dogs, along with regulatory grants, conditional approval renewals, and studies designed to support full approval. Updates may also address efforts to obtain guidance from the European Medicines Agency for Canalevia in general diarrhea in dogs.
Corporate and capital markets announcements are another key component of JAGX news. These can include securities purchase agreements, royalty interest amendments, PIPE financings, preferred stock exchanges, and at-the-market offering amendments, as disclosed in Form 8-K filings. Conference presentations, investor summit appearances, and summaries of stockholder meeting results also appear in the company’s news flow.
For investors and observers, the Jaguar Health news page provides a centralized view of clinical, regulatory, commercial, and financing developments that shape the company’s strategy in plant-based gastrointestinal therapeutics for both human and veterinary medicine.
Jaguar Health (NASDAQ:JAGX) announced positive results from two investigator-initiated studies of crofelemer, its plant-based oral drug, for chronic refractory diarrhea in IBS-D patients. The data will be presented at the American College of Gastroenterology Annual Scientific Meeting in October 2024. Key findings include:
1. In functional diarrhea: Crofelemer significantly decreased stool consistency and abdominal pain without major side effects in a small crossover study of 18 patients.
2. In chronic idiopathic diarrhea: Nearly 60% of patients showed improvement within a 4-week treatment period.
These results suggest crofelemer's potential efficacy in treating subgroups of IBS-D, addressing an unmet need in gastroenterology. The company plans to continue investigating crofelemer for IBS-D management.
Jaguar Health (NASDAQ:JAGX) announced that its subsidiary, Napo Pharmaceuticals, has been granted a new European patent for treating diarrhea associated with congenital diarrheal disorders (CDDs) using crofelemer, a plant-based drug. This patent strengthens Jaguar's intellectual property protection for its core rare disease target indication, particularly for microvillus inclusion disease (MVID), an ultrarare CDD.
The company is supporting investigator-initiated proof-of-concept studies for crofelemer in treating short bowel syndrome (SBS) and MVID across the US, EU, and Middle East/North Africa regions. Results are expected by the end of 2024 and throughout 2025. Jaguar now holds approximately 200 patents issued and pending, with crofelemer being the only oral plant-based prescription medicine approved under the FDA's Botanical Guidance.
Jaguar Health (NASDAQ:JAGX) announced results from its Phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy. The trial did not meet its primary endpoint across all tumor types. However, it revealed clinically relevant signals for crofelemer in prespecified subgroups of patients with breast and respiratory cancer, including lung cancer. These subgroups comprised over 75% of trial participants.
Key takeaways:
- Trial included 10 tumor types and 24 targeted agents
- Positive signals improved over the initial 12-week phase
- Crofelemer was well-tolerated with an adverse event profile similar to placebo
- Company plans to engage with FDA after full data review
Jaguar will host an investor webcast on July 23, 2024, to provide updates on its cancer supportive care portfolio.
Jaguar Health (NASDAQ:JAGX) will report results of its Phase 3 OnTarget trial for crofelemer, a cancer supportive care drug, on July 23, 2024. The company will hold an investor webcast at 8:30 AM Eastern to discuss the results and provide updates on its cancer supportive care portfolio. The webcast will feature Jaguar's scientific team, patient advocates, and oncology experts focusing on cancer therapy-related diarrhea (CTD) and oral mucositis.
Jaguar has expanded its 'Make Cancer Less Shitty' (MCLS) patient advocacy program, incorporating MCLS Ambassadors who are cancer survivors. The company also entered a 5-year U.S. in-license agreement for Gelclair, an FDA-approved oral mucositis product. These initiatives aim to address the significant impact of treatment side effects on cancer patients' quality of life and treatment adherence.
Jaguar Health has announced the issuance of new patents in Europe and Australia to bolster IP protection for its drug crofelemer, aimed at treating Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs). The European patent covers treatment methods for SBS and associated conditions, while the Australian patent focuses on CDDs. The patents enhance Jaguar's intellectual property portfolio, which already includes approximately 200 patents issued or pending. This development supports ongoing proof-of-concept studies of crofelemer in the US, EU, and MENA regions, with results expected in 2024 and 2025. These studies could facilitate early patient access to crofelemer in countries with applicable guidelines. SBS and MVID patients suffer from severe symptoms requiring intensive medical support, highlighting the potential impact of these patents on patient care.
Jaguar Health (NASDAQ: JAGX) has announced that it has regained compliance with Nasdaq's bid price requirement as of June 25, 2024, ensuring its securities remain listed and traded on Nasdaq. The company is also set to report results from its pivotal phase 3 OnTarget trial for the cancer supportive care drug crofelemer by July 23, 2024. Jaguar's CEO, Lisa Conte, emphasized the importance of maintaining their Nasdaq listing and mentioned an upcoming investor webcast that will discuss Jaguar's cancer supportive care portfolio, featuring insights from scientific experts and patient advocates.
Jaguar Health announced the approval of all proposals at its Annual Meeting of Stockholders held on June 21, 2024. Five proposals were submitted and approved, details of which are available in the company's proxy statement filed with the SEC. Jaguar will report results from its pivotal phase 3 OnTarget trial for the cancer supportive care drug crofelemer by July 23, 2024. An investor webcast on or before this date will include updates on Jaguar's cancer supportive care portfolio, featuring insights from the scientific team, patient advocates, and oncology experts. In celebration of World Rainforest Day on June 22, Jaguar shared a RealPharma podcast interview with Dr. Steven King, highlighting his ethnobotanical research and the medicinal use of plants by indigenous Amazonian communities.
Jaguar Health announced it will release the results of its phase 3 OnTarget trial for crofelemer, aimed at preventing diarrhea in cancer patients, by July 23, 2024. The study involves patients with solid tumors undergoing targeted therapy, with or without chemotherapy. An investor webcast will present the trial results and updates on Jaguar's cancer supportive care initiatives. Key points include Jaguar's in-license of Gelclair for oral mucositis, a commercialization deal with GEN for crofelemer in Turkey, and the 'Make Cancer Less Shitty' advocacy program. The company emphasizes the importance of supportive care in improving cancer patients' quality of life.
Jaguar Health announced a new employee inducement grant under Nasdaq Listing Rule 5635(c)(4), effective June 4, 2024. The company has granted 1,111 restricted stock units (RSUs) to a new employee, which will vest over one year. This grant, approved by Jaguar's Compensation Committee, was made to attract the new hire. The vesting of these RSUs is contingent upon the employee's continued service with Jaguar through the vesting period.
Jaguar Health has announced an out-licensing agreement with Magdalena Biosciences for a botanical drug candidate aimed at treating schizophrenia. This drug shows antipsychotic activity with a unique mechanism of action compared to current FDA-approved therapies. Under the deal, Jaguar will receive 10% of all upfront and milestone payments, excluding certain commercial milestones and R&D reimbursements. Additionally, Jaguar will earn royalties on net sales if the drug is FDA-approved and commercialized. The U.S. schizophrenia market is forecasted to reach $8.06 billion by 2030. Jaguar will present at the Lytham Partners Spring 2024 Investor Conference on May 30.